Education
About Us
Working with TipRanks
Follow Us
BioGaia AB Class B (GB:0GTN)
LSE:0GTN
0GTN Stock Chart & Stats
kr105.70
kr1.00(0.90%)
At close: 4:00 PM EST
kr105.70
kr1.00(0.90%)
Day’s Range― - ―
52-Week Rangekr93.60 - kr119.50
Previous CloseN/A
Volume2.49K
Average Volume (3M)6.59K
Market Cap
kr11.51B
Enterprise Valuekr10.29B
Total Cash (Recent Filing)kr801.31M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)32.3
Beta0.56
Next Earnings
May 13, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding98,497,170
10 Day Avg. Volume4,070
30 Day Avg. Volume6,588
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.05
Revenue Forecast (FY)kr1.64B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthMulti-year revenue expansion demonstrates durable market demand and successful commercial execution across geographies and channels. Sustained top-line growth supports scale benefits, funds R&D/marketing, and underpins long-term product investments and partner relationships even if margins ebb.
Very Conservative Balance SheetNear-zero leverage and no reported debt provide strong financial flexibility for strategic investments, downturn resilience, and partner financing. This low financial risk profile preserves optionality for M&A, geographic expansion, or clinical development without heavy interest burdens.
Strong Cash Generation QualityOperating cash conversion materially above accounting earnings and FCF closely tracking net income indicate high earnings quality and reliable internal funding. That supports reinvestment, modest dividends and partner commitments without needing external financing.
Bears Say
Margin Compression Since 2022Declining net margins over multiple years signal rising cost pressures or heavier investment that materially reduces retained profits. Persistently lower margins can weaken free cash flow, limit reinvestment capacity, and make future profitability more sensitive to revenue volatility.
Declining Equity BaseA sizable drop in shareholders' equity over a short period reduces the cushion against losses and may reflect cumulative earnings pressure or capital deployment that erodes book value. Lower equity constrains leverage capacity and could limit strategic financing flexibility.
Weaker Recent Cash ConversionA recent decline in FCF despite higher revenues indicates narrowing cash conversion, raising the risk that operational costs or working capital shifts are eroding cash available for shareholders or reinvestment. If persistent, this reduces financial optionality.
BioGaia AB News
0GTN FAQ
What was BioGaia AB Class B’s price range in the past 12 months?
BioGaia AB Class B lowest share price was kr93.60 and its highest was kr119.50 in the past 12 months.
What is BioGaia AB Class B’s market cap?
BioGaia AB Class B’s market cap is kr11.51B.
When is BioGaia AB Class B’s upcoming earnings report date?
BioGaia AB Class B’s upcoming earnings report date is May 13, 2026 which is in 51 days.
How were BioGaia AB Class B’s earnings last quarter?
BioGaia AB Class B released its earnings results on Feb 12, 2026. The company reported kr0.98 earnings per share for the quarter, beating the consensus estimate of kr0.8 by kr0.18.
Is BioGaia AB Class B overvalued?
According to Wall Street analysts BioGaia AB Class B’s price is currently Overvalued.
Does BioGaia AB Class B pay dividends?
BioGaia AB Class B does not currently pay dividends.
What is BioGaia AB Class B’s EPS estimate?
BioGaia AB Class B’s EPS estimate is 0.84.
How many shares outstanding does BioGaia AB Class B have?
BioGaia AB Class B has 98,497,170 shares outstanding.
What happened to BioGaia AB Class B’s price movement after its last earnings report?
BioGaia AB Class B reported an EPS of kr0.98 in its last earnings report, beating expectations of kr0.8. Following the earnings report the stock price went down -5.825%.
Which hedge fund is a major shareholder of BioGaia AB Class B?
Currently, no hedge funds are holding shares in GB:0GTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioGaia AB Class B
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylorithe gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---